A life-threatening ruxolitinib discontinuation syndrome. (Q47906964)

6 February 2018

title

A life-threatening ruxolitinib discontinuation syndrome. (English)

1 reference

6 February 2018

1 reference

3

1 reference

6 February 2018

Alessandro Maria Vannucchi

object named as

Alessandro Maria Vannucchi

6

0 references

Alberto Bosi

object named as

Alberto Bosi

5

0 references

author name string

Giacomo Coltro

1

1 reference

6 February 2018

Francesco Mannelli

2

1 reference

6 February 2018

Annalisa Pacilli

4

1 reference

6 February 2018

publication date

29 April 2017

1 reference

6 February 2018

American Journal of Hematology

published in

1 reference

6 February 2018

volume

92

1 reference

6 February 2018

issue

8

1 reference

6 February 2018

page(s)

833-838

1 reference

6 February 2018

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

cites work

1 reference

Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management

21 January 2018

1 reference

Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).

21 January 2018

1 reference

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

21 January 2018

1 reference

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

21 January 2018

1 reference

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

21 January 2018

1 reference

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

21 January 2018

1 reference

Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study

21 January 2018

1 reference

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

21 January 2018

1 reference

JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib.

21 January 2018

1 reference

Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis

21 January 2018

1 reference

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis

21 January 2018

1 reference

Ruxolitinib withdrawal syndrome leading to tumor lysis

21 January 2018

1 reference

Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation

21 January 2018

1 reference

Recurrent hypoxemic respiratory failure. Beyond the usual suspects.

21 January 2018

1 reference

Pathogenesis of myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.24775

1 reference

6 February 2018

PubMed ID

28457008

1 reference

6 February 2018